Dr. Oren Hershkovitz, CEO, and Einat Galamidi, MD, CMO, will attend the conference and be available for meetings with stakeholders and members of the scientific community. Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June ...

Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21– 23, 2025 in Tel Aviv, Israel. The Company's presentation is titled "Enlivex—Harnessing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage.   Oren Hershkovitz, Ph.D, CEO of Enlivex, co ...

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ causes pain and stiffness in the jaw, making it difficult to chewTMJ osteoarthritis currently has no long-term effective treatments Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company" or "Enlivex")), a clinical-stage macrophage reprogramming immunother ...

Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for patent application number 2020800620493. Once issued, the resulting patent will provide Enlivex with added intellectual property protection in China through at least 2040 with claims covering methods of using Allocetra ...

Core Insights - Enlivex Therapeutics Ltd. is hosting a live investor webinar on March 5, 2025, to discuss positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis [1][4] Group 1: Trial Results - The interim results from the Allocetra™ trial showed a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment [2] - 83% of treated patients were still considered responders to treatment at six months, indicating the durability and sustained efficacy of Allocetra™ [2][3] - No serious adverse events were reported, reinforcing the favorable safety profile of Allocetra™ [2] Group 2: Company Commitment - The CEO of Enlivex expressed excitement about the promising interim results, highlighting Allocetra™'s potential to provide meaningful and sustained pain relief for patients with moderate to severe knee osteoarthritis [3] - The company remains committed to advancing this innovative therapy to unlock its full potential for millions of patients worldwide [3] Group 3: Webinar Details - The webinar will feature a detailed review of the interim results and will include a live Q&A session [4] - Interested investors can register for the free webinar through the provided link [4]

Core Insights - Enlivex Therapeutics Ltd. announced positive interim six-month efficacy data from the Phase I stage of its Allocetra™ trial for knee osteoarthritis, showing significant pain reduction and improved functionality [1][2][4] Company Overview - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune balance [6] Clinical Trial Details - The Phase I/II trial consists of two stages: the completed Phase I safety run-in and the ongoing Phase II double-blind, randomized, placebo-controlled trial [1][3] - The Phase I stage demonstrated a 47.0% average reduction in reported pain and significant improvements in functionality and stiffness, with 83% of patients still responding to treatment after six months [2][4] Efficacy Results - The six-month interim results showed a 51.2% reduction in WOMAC pain, a 46% improvement in WOMAC function, and a 40% improvement in WOMAC stiffness, indicating durable efficacy [2][4] - The safety profile of Allocetra™ remained consistent, with no serious adverse events reported [2][4] Osteoarthritis Context - Osteoarthritis is the most common form of arthritis, affecting over 32.5 million Americans and projected to reach 78 million by 2040, highlighting the critical need for effective treatments [4][5]

Core Viewpoint - Enlivex Therapeutics Ltd. has denied false claims made by Tipranks.com regarding the suspension of its stock trading due to an internal investigation, asserting that the company continues to operate normally and its shares are trading regularly on both the Tel Aviv Stock Exchange and NASDAQ [1][2]. Company Operations - The company emphasizes that it is executing its operating plan and is optimistic about the potential of its product Allocetra™ to provide treatment solutions for osteoarthritis patients, who currently have limited options [3]. - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, which aims to reset non-homeostatic macrophages to their homeostatic state, crucial for immune system rebalancing [4]. Legal Actions - The CEO of Enlivex has stated that the company will pursue legal actions against those responsible for the false report, including the publishers and hosting service of Tipranks.com [3]. Investor Communication - The company urges investors to rely solely on official communications, including press releases and filings with the U.S. Securities and Exchange Commission, for accurate information [2].

Core Viewpoint - Enlivex Therapeutics Ltd. has received authorization from the Israeli Ministry of Health to initiate a Phase I trial for Allocetra™ in patients with temporomandibular joint (TMJ) osteoarthritis, aiming to evaluate its safety, tolerability, and initial efficacy [1][3]. Company Overview - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, a universal, off-the-shelf cell therapy designed to restore macrophages to their homeostatic state [4][6]. - The company aims to address unmet medical needs in various conditions, including solid cancers and sepsis, by reprogramming non-homeostatic macrophages [4][6]. Industry Context - TMJ disorders are the second most common musculoskeletal condition, affecting 5% to 12% of the global population, with an estimated annual health cost of $4 billion [5]. - TMJ osteoarthritis is the most prevalent form of arthritis in the TMJ, leading to significant pain and functional impairment, and currently lacks effective long-term treatment options [5]. Clinical Trial Details - The Phase I trial will be conducted by the Rheumatology Unit at Sheba Medical Center, which is recognized among the top 10 hospitals globally [2]. - The trial aims to recruit six patients who have not responded adequately to conventional treatments, with primary endpoints focusing on safety and secondary endpoints assessing pain and joint functionality over 12 months [3].